Class III is the highest risk category under the EU Medical Device Regulation. Every Class III device needs a Notified Body, the technical documentation is assessed per device under Annex IX, the clinical evidence bar is set by Article 61 with a default requirement to perform clinical investigations under Article 61(4), and implantable Class III devices and certain Class III active devices trigger the clinical evaluation consultation procedure under Article 54 and the scrutiny mechanism under Article 55. Typical Class III devices include heart valves, coronary stents, active implantables, absorbable sutures, and SaMD whose decisions could cause death or irreversible deterioration of health. Class III is not a step up from Class IIb — it is a different league, and a startup should only enter it with clear eyes about what that means.

By Tibor Zechmeister and Felix Lenhard. Last updated 10 April 2026.

TL;DR

  • Class III is the highest risk class under Regulation (EU) 2017/745. The class is assigned by applying the classification rules in Annex VIII to the device's intended purpose — it is not chosen by the manufacturer.
  • Every Class III device requires Notified Body involvement. The conformity assessment procedures are set out in Article 52 and carried out under Annex IX, or under a combination of Annex X type examination and Annex XI production conformity verification where the Regulation permits.
  • Article 61(4) establishes the default that confirmation of conformity with the relevant general safety and performance requirements for implantable devices and Class III devices shall be based on clinical data from clinical investigations. Narrow exemptions exist under Article 61(4), 61(5), and 61(6), clarified by MDCG 2023-7.
  • Implantable Class III devices and certain Class IIb active devices intended to administer or remove a medicinal product trigger the clinical evaluation consultation procedure under Article 54, carried out by an expert panel.
  • Article 55 establishes the scrutiny procedure: the Notified Body notifies the competent authority of certain Class III and implantable device certification decisions, and summaries of safety and clinical performance are made publicly available via Eudamed.
  • Clinical investigations follow the requirements of Articles 62 to 82 and Annex XV, conducted in accordance with EN ISO 14155:2020 + A11:2024.
  • For many early-stage startups, Class III is the class where the honest conversation is whether to pursue it at all — not whether to pursue it cheaply.

What Class III actually means

Class III is the highest risk category under the MDR. Under Article 51 of Regulation (EU) 2017/745, devices are classified as Class I, IIa, IIb, or III, taking into account the intended purpose of the devices and their inherent risks. Class III captures devices where a failure mode can cause death or an irreversible deterioration of health, where the device interacts with the central circulatory system or the central nervous system, where it has a biological effect, where it is absorbed by the body, where it administers a medicinal product, or where it performs functions that the regulator has judged to require the highest level of scrutiny.

The practical meaning for a founder is that Class III is not an incremental step up from Class IIb. It is a different regulatory universe. The default evidentiary requirement shifts from literature-based clinical evaluation to clinical investigation. The certification process adds a clinical evaluation consultation procedure with an expert panel under Article 54 for implantable Class III devices. The Notified Body's decision feeds into a scrutiny procedure under Article 55. The technical documentation review is per device under Annex IX. The post-market obligations are heavier. The cost, the timeline, and the failure modes are all different in kind, not just in degree.

This does not mean Class III is unreachable for a startup. It means Class III is the place where the STS discipline matters most — and where a founder who cannot articulate why their device is Class III with a specific Annex VIII rule citation has already lost the project.

Typical Class III devices

Classification is always the output of applying Annex VIII rules to the actual intended purpose. In practice, Class III devices cluster in a few recognisable families.

Implantable devices with escalation triggers. Heart valves, coronary stents, vascular grafts in contact with the central circulatory system, spinal cages in direct contact with the central nervous system, long-term implantable joint replacements of certain types, and absorbable implants fall into Class III through Rule 8 and related rules. The trigger is usually contact with the heart, the central circulatory system, or the central nervous system, or a biological effect, absorption, or administration of a medicinal product.

Active implantable devices. Pacemakers, implantable cardioverter-defibrillators, implantable neurostimulators, and cochlear implants are Class III under the rules governing active implantable devices. The former Active Implantable Medical Devices Directive regime no longer exists as a separate track — the MDR brought active implantables into the unified classification framework, and they now sit firmly in Class III.

Devices incorporating a medicinal substance or derivatives of tissues and cells. Drug-eluting stents, certain bone cements containing antibiotics, and devices incorporating non-viable human or animal tissues or derivatives are Class III where the rules assign them there. These devices also trigger additional consultation procedures with medicines authorities under Article 52 and related provisions.

SaMD at the top of Rule 11. Software intended to provide information used to make decisions with diagnostic or therapeutic purposes is Class III under Rule 11 where those decisions may cause death or an irreversible deterioration of a person's state of health. This branch of Rule 11 captures a narrow but growing set of high-stakes clinical decision support and autonomous diagnostic software.

The specific class for any real device must always be determined by reading Annex VIII, applying the rules to the actual intended purpose, and documenting the decision with a specific rule citation. Class III is not assigned by intuition.

Mandatory clinical investigation under Article 61(4)

Article 61 governs clinical evaluation. For Class III and implantable devices, Article 61(4) is the provision that reshapes the project.

"For implantable devices and class III devices, clinical investigations shall be performed, except if [the narrow conditions set out in the paragraph apply]." — Regulation (EU) 2017/745, Article 61, paragraph 4, in substance.

The default is clinical investigations. A manufacturer developing an implantable device or a Class III device must plan from day one for clinical investigations designed and conducted under Articles 62 to 82 and Annex XV, following EN ISO 14155:2020 + A11:2024 as the good clinical practice standard for clinical investigations of medical devices. This is a substantial operational and financial commitment — sites, investigators, ethics approvals, competent authority authorisations, monitoring, adverse event reporting, data management, statistical analysis, and a clinical study report that can survive Notified Body review.

Clinical investigations for Class III devices are not a box-ticking exercise. They are the load-bearing evidence that the device is safe and performs as intended for the foreseeable conditions of use. A weak clinical investigation is the most expensive mistake a Class III project can make, because it cannot be fixed retrospectively — the only remedy is running more investigation, which resets the timeline.

MDCG 2023-7 and the Article 61(4)-(6) exemptions

Article 61(4), 61(5), and 61(6) define the narrow cases where a clinical investigation may not be required for an implantable or Class III device. MDCG 2023-7, published December 2023, is the authoritative guidance on how those exemptions are applied.

The exemptions fall into four broad patterns set out in the Regulation and clarified by MDCG 2023-7. In summary: where the device is modified from a device already marketed by the same manufacturer and equivalence can be demonstrated with sufficient clinical data; where the device is equivalent to a device already marketed by another manufacturer and there is a contract providing sufficient levels of access to the technical documentation on an ongoing basis; where the device is based on well-established technologies listed in Article 61(6) (such as sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips, and connectors); and where clinical investigations would be inappropriate and the clinical evaluation is based on sufficient clinical data in accordance with the common specifications or harmonised standards for the device type, where available.

Each exemption is narrow. Each one requires careful reading of the exact text, the MDCG 2023-7 guidance, and an honest assessment of whether the evidence package actually meets the bar. The phrase "sufficient levels of access to the technical documentation on an ongoing basis" is the part of the equivalence exemption that most manufacturers underestimate — it typically requires a written contract with the comparator manufacturer, not a marketing brochure and a literature search.

For a startup, the practical question is whether any of these exemptions is realistically available for the specific device in scope. If the answer is no, the clinical investigation is the plan and should be budgeted accordingly. If the answer is maybe, the plan should cover both the exemption case and the fallback investigation — because assuming the exemption will hold and being told otherwise mid-review is a runway event.

The Article 54 clinical evaluation consultation procedure

Article 54 establishes the clinical evaluation consultation procedure for certain Class III and Class IIb devices. In summary, the procedure requires Notified Bodies to follow a specific consultation pathway in which an expert panel provides a scientific opinion on the clinical evaluation assessment report prepared by the Notified Body.

Article 54 applies to implantable Class III devices, with narrowly defined exceptions (including certain devices that are modifications of devices already marketed by the same manufacturer, certain well-established devices, and where the Notified Body has already assessed the clinical evaluation of a comparable device from the same manufacturer). Article 54 also applies to certain Class IIb active devices intended to administer or remove a medicinal product.

The operational reality is that the Article 54 consultation adds time to the certification path. The Notified Body prepares a clinical evaluation assessment report, submits it to the Commission, and an expert panel reviews the report against the manufacturer's evidence and issues a scientific opinion. The Notified Body then gives due consideration to the opinion when reaching its certification decision. The timelines and procedural details are set out in Article 54 and the implementing framework around it, and they must be read in the actual Regulation before being built into a project plan.

The procedural rigour of Article 54 is not bureaucratic overhead — it exists because the consequences of a wrong Class III certification decision on an implantable device are measured in patient harm, not commercial delay. A founder who resents the Article 54 procedure is, in effect, resenting the thing that makes the CE mark on a Class III implant mean something.

The Article 55 scrutiny procedure

Article 55 establishes the scrutiny procedure. For certain Class III devices and implantable devices, the Notified Body notifies the competent authority of its certification decisions, and the competent authority may trigger additional review where justified. Summaries of safety and clinical performance are made publicly available via Eudamed for Class III and implantable devices, under the transparency obligations in the Regulation.

The practical effect is that Class III certification is not a private conversation between manufacturer and Notified Body. It is visible to competent authorities and, in summary form, to the public. The transparency increases the pressure on the Notified Body to get every decision right, and it increases the pressure on the manufacturer to build a technical file that can survive scrutiny from readers who were not in the room.

Article 55 is not optional and cannot be routed around. Planning a Class III project without understanding the Article 55 scrutiny procedure and the public-facing summary obligations is planning with incomplete information.

Cost and timeline reality

Class III certification honestly runs eighteen to thirty-six months from QMS-ready state to certificate for a first device, with wide variance. The clinical investigation alone often takes twelve to twenty-four months when enrolment, follow-up, and analysis are all counted, and that runs in parallel with the technical documentation build but ultimately gates the Notified Body submission. The Article 54 consultation adds time. The Notified Body review under Annex IX runs multiple rounds.

The honest cost is meaningfully higher than Class IIb. Notified Body fees for a first Class III device run into mid to high six-figure euros in many cases, before internal effort, consultants, clinical investigation costs, external testing, and regulatory operations overhead. Clinical investigation costs for a single pivotal study at a small number of sites commonly run from mid six figures to low seven figures, depending on sample size, endpoints, duration of follow-up, and geography. These numbers are ranges, every project is different, and exceptional projects run leaner — but a Class III plan budgeted on the basis of best-case numbers is a plan that will not survive first contact with reality.

Should a startup pursue Class III at all?

The honest answer is: sometimes, with clear eyes. Some devices genuinely belong in Class III, and some startups genuinely have the team, the capital, the clinical access, and the strategic patience to reach a Class III certificate. The rest should ask whether the product wedge can legitimately be narrowed to a Class IIb or Class IIa device that reaches the market, generates evidence and revenue, and funds the Class III follow-on. Sometimes that narrowing is available and sometimes it is not — but the question has to be asked explicitly, not by default.

The worst version of a Class III project is the one where the founder did not realise the device was Class III until a reviewer pointed it out. The second-worst version is the one where the founder knew the device was Class III but built the plan on Class IIb assumptions. The best version is the one where the founder accepted Class III from day one, built the clinical investigation into the critical path, selected the Notified Body on scope match for Class III in the specific device category, and raised the capital that a Class III plan actually requires.

Class III is not a place to end up by accident.

The Subtract to Ship angle on Class III

The Subtract to Ship framework does not promise to make Class III cheap. It promises to make Class III survivable by cutting every activity that does not trace to a specific MDR article, annex, or harmonised standard clause — and at Class III, the list of defensible activities is long, so the discipline matters even more.

Classify under Annex VIII with a specific rule citation, and check every escalation criterion that might push the device into Class III or pull it out. Where the classification is genuinely borderline, read the Borderline Manual and the MDCG guidance, and make the decision explicitly. Choose the Notified Body on scope match for the specific Class III device category — not every Notified Body has active implantable scope, not every Notified Body has heart valve experience, and the scope match dominates every other selection criterion at Class III. Build the clinical investigation plan under Articles 62 to 82 and Annex XV in accordance with EN ISO 14155:2020 + A11:2024 from day one, and if an Article 61(4)-(6) exemption is being pursued, build the fallback investigation plan in parallel. Build the risk management file against EN ISO 14971:2019 + A11:2021 and couple it tightly to the clinical evaluation and the post-market clinical follow-up plan. Plan for the Article 54 consultation and the Article 55 scrutiny as part of the critical path, not as surprises. Cut every document and every activity that cannot be tied to a specific requirement — because at Class III, every unnecessary page is a page the reviewer and the expert panel have to work through.

The framework does not make Class III easy. Nothing makes Class III easy. The framework makes Class III honest — which is the precondition for making it at all.

Reality Check — Where do you stand on Class III?

  1. Have you classified your device under Annex VIII with a specific rule citation and checked every Class III escalation criterion that might apply?
  2. Have you confirmed whether your device is implantable, and if so, whether Article 54 clinical evaluation consultation applies?
  3. Do you have a clinical investigation plan under Articles 62 to 82 and Annex XV, designed in accordance with EN ISO 14155:2020 + A11:2024, with realistic sample size, endpoints, and duration of follow-up?
  4. If you intend to rely on an Article 61(4)-(6) exemption, have you read MDCG 2023-7 and confirmed the specific exemption applies to your device with documented evidence?
  5. Have you selected a Notified Body whose scope covers your specific Class III device category and whose capacity realistically matches your timeline?
  6. Have you planned for the Article 55 scrutiny procedure and the public summary of safety and clinical performance obligations?
  7. Is your risk management file under EN ISO 14971:2019 + A11:2021 built and coupled to the clinical evaluation and the post-market clinical follow-up plan?
  8. Have you budgeted realistic Class III ranges for time, clinical investigation costs, and Notified Body fees — not Class IIb assumptions with a markup?
  9. Have you asked explicitly whether the product wedge could legitimately be narrowed to a lower class that reaches the market first, and documented the decision?
  10. Can you defend every activity in your Class III plan by pointing to a specific article, annex, or harmonised standard clause?

Frequently Asked Questions

What makes a device Class III under the MDR? A device is Class III when the classification rules in Annex VIII of Regulation (EU) 2017/745 assign it there. The common triggers include contact with the central circulatory system or the central nervous system, a biological effect, absorption by the body, administration of a medicinal product, active implantable function, or (under Rule 11) software whose decisions may cause death or irreversible deterioration of health. The class is the output of the rules applied to the actual intended purpose — not a label chosen by the manufacturer.

Is a clinical investigation always required for a Class III device? No, but the default under Article 61(4) is that clinical investigations shall be performed for implantable devices and Class III devices. Narrow exemptions exist in Article 61(4), 61(5), and 61(6), clarified by MDCG 2023-7, covering modifications of existing devices from the same manufacturer, equivalence to a device from another manufacturer with sufficient levels of access to the technical documentation, well-established technologies listed in Article 61(6), and cases where investigations would be inappropriate. Each exemption is narrow and must be justified explicitly.

What is the Article 54 clinical evaluation consultation procedure? Article 54 requires Notified Bodies to follow a consultation pathway in which an expert panel provides a scientific opinion on the clinical evaluation assessment report for certain Class III and Class IIb devices, including implantable Class III devices (with narrow exceptions) and certain Class IIb active devices intended to administer or remove a medicinal product. The Notified Body gives due consideration to the expert panel's scientific opinion when reaching its certification decision. The procedure adds time to the certification path and must be planned as part of the critical path.

What is the Article 55 scrutiny procedure? Article 55 establishes a scrutiny mechanism for certain Class III and implantable devices, including notification of Notified Body certification decisions to the competent authority and the public availability of summaries of safety and clinical performance via Eudamed. It makes Class III certification visible beyond the bilateral manufacturer-Notified Body relationship and reinforces the quality bar on every decision.

How long does a Class III conformity assessment take for a startup? The honest order of magnitude is eighteen to thirty-six months from QMS-ready state to certificate for a first Class III device, with the clinical investigation often taking twelve to twenty-four months on its own. Article 54 consultation adds time. Multiple rounds of Notified Body review are the norm, not the exception. Exceptional projects run faster; weak clinical evidence or poor Notified Body fit can push timelines well past the upper end of the range.

Can a startup realistically pursue a Class III device? Yes, but only with clear eyes. Class III is not unreachable, but it is not a default route — it requires the team, capital, clinical access, and strategic patience that a Class III plan honestly needs. The explicit question every founder should ask is whether a legitimate narrower intended purpose would place the first device in a lower class, reach the market sooner, and fund the Class III follow-on. Sometimes the answer is no and Class III is the only honest path; sometimes the answer is yes and the Class III assumption was premature.

Which harmonised standards apply specifically at Class III? The same horizontal standards apply across classes — EN ISO 14971:2019 + A11:2021 for risk management, and the QMS standard EN ISO 13485:2016 + A11:2021 — with device-specific standards on top (electrical safety, EMC, biocompatibility, software lifecycle, cybersecurity, and so on, depending on the device). The clinical investigation standard specific to Class III projects is EN ISO 14155:2020 + A11:2024, which defines good clinical practice for clinical investigations of medical devices for human subjects.

Sources

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Article 51 (classification), Article 52 (conformity assessment procedures), Article 54 (clinical evaluation consultation procedure for certain Class III and Class IIb devices), Article 55 (scrutiny mechanism regarding conformity assessments of certain Class III and Class IIb devices), Article 61 (clinical evaluation), Article 61(4)-(6) (clinical investigation requirement and exemptions), Annex VIII (classification rules), Annex IX (conformity assessment based on a quality management system and on assessment of technical documentation), Annex XIV (clinical evaluation and post-market clinical follow-up). Official Journal L 117, 5.5.2017.
  2. MDCG 2023-7 — Guidance on exemptions from the requirement to perform clinical investigations pursuant to Article 61(4)-(6) MDR and on 'sufficient levels of access' to data needed to justify claims of equivalence, December 2023.
  3. EN ISO 14155:2020 + A11:2024 — Clinical investigation of medical devices for human subjects — Good clinical practice.
  4. EN ISO 14971:2019 + A11:2021 — Medical devices — Application of risk management to medical devices.

This post is part of the Device Classification & Conformity Assessment series in the Subtract to Ship: MDR blog. Authored by Felix Lenhard and Tibor Zechmeister. Class III is where honesty about the plan matters more than any framework — a startup that reaches a Class III certificate does it by accepting the clinical investigation, the Article 54 consultation, the Article 55 scrutiny, and the per-device Annex IX review as the critical path from day one, and by cutting everything that does not trace to a specific MDR article, annex, or harmonised standard clause.